Minodronic acid

Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain.

Product information

CAS Number: 180064-38-4

Molecular Weight: 322.15

Formula: C9H12N2O7P2

Synonym:

YM-529

Chemical Name: (1-hydroxy-2-{imidazo[1, 2-a]pyridin-3-yl}-1-phosphonoethyl)phosphonic acid

Smiles: OC(CC1=CN=C2C=CC=CN21)(P(O)(O)=O)P(O)(O)=O

InChiKey: VMMKGHQPQIEGSQ-UHFFFAOYSA-N

InChi: InChI=1S/C9H12N2O7P2/c12-9(19(13,14)15,20(16,17)18)5-7-6-10-8-3-1-2-4-11(7)8/h1-4,6,12H,5H2,(H2,13,14,15)(H2,16,17,18)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: H2O : 5 mg/mL (15.52 mM; Need ultrasonic and warming) DMSO : < 1 mg/mL (insoluble or slightly soluble)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

References:

1. Sato K, et al. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer. 2006 Nov 20;95(10):1354-61.
2. Tanaka M, et al. Minodronic acid induces morphological changes in osteoclasts at bone resorption sites and reaches a level required for antagonism of purinergic P2X2/3 receptors. J Bone Miner Metab. 2018 Jan;36(1):54-63.

Products are for research use only. Not for human use.